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ABSTRACT
Introduction Molecular characterisation of tumours is
increasing personalisation of cancer therapy, tailored to
an individual and their cancer. FOCUS4 is a molecularly
stratiﬁed clinical trial for patients with advanced
colorectal cancer. During an initial 16-week period of
standard ﬁrst-line chemotherapy, tumour tissue will
undergo several molecular assays, with the results used
for cohort allocation, then randomisation. Laboratories in
Leeds and Cardiff will perform the molecular testing. The
results of a rigorous pre-trial inter-laboratory analytical
validation are presented and discussed.
Methods Wales Cancer Bank supplied FFPE tumour
blocks from 97 mCRC patients with consent for use in
further research. Both laboratories processed each
sample according to an agreed deﬁnitive FOCUS4
laboratory protocol, reporting results directly to the MRC
Trial Management Group for independent cross-
referencing.
Results Pyrosequencing analysis of mutation status at
KRAS codons12/13/61/146, NRAS codons12/13/61,
BRAF codon600 and PIK3CA codons542/545/546/1047,
generated highly concordant results. Two samples gave
discrepant results; in one a PIK3CA mutation was
detected only in Leeds, and in the other, a PIK3CA
mutation was only detected in Cardiff. pTEN and
mismatch repair (MMR) protein expression was assessed
by immunohistochemistry (IHC) resulting in 6/97
discordant results for pTEN and 5/388 for MMR,
resolved upon joint review. Tumour heterogeneity was
likely responsible for pyrosequencing discrepancies. The
presence of signet-ring cells, necrosis, mucin, edge-
effects and over-counterstaining inﬂuenced IHC
discrepancies.
Conclusions Pre-trial assay analytical validation is
essential to ensure appropriate selection of patients for
targeted therapies. This is feasible for both mutation
testing and immunohistochemical assays and must be
built into the workup of such trials.
Trial registration number ISRCTN90061564.
INTRODUCTION
Molecular characterisation of tumours is leading
to increasing personalisation of cancer therapy
tailored to an individual and the target cancer.
FOCUS4 (ﬁgure 1) marks a signiﬁcant advance-
ment in terms of clinical trial design.1 It aims to
stratify patients to novel targeted agents by a pro-
spective, progressive molecular stratiﬁcation
process. Following patient registration, archival
formalin-ﬁxed, parafﬁn-embedded (FFPE) tumour
samples from patients with advanced or metastatic
colorectal cancer (CRC) will be sent from collabor-
ating centres to undergo mutation and immunohis-
tochemical testing at one of the two centralised
testing laboratories in Leeds and Cardiff, to allow
the allocation of patients into molecular cohorts,
within which there is a speciﬁc randomised
comparison.
The current panel of molecular markers selected
for the trial is based on biomarkers which have
been identiﬁed or are hypothesised as having the
capacity to predict responses to speciﬁc targeted
therapies. The trial is designed to allow the panel
to progressively change during the life span of the
trial, with identiﬁcation of novel biomarkers and
new treatment approaches being incorporated for
differing biomarker-deﬁned cohorts.1
Mutational analysis of KRAS and NRAS is already
used routinely to determine suitability to receive
anti-epidermal growth factor receptor (EGFR)
therapy.2–5 Mutational status of BRAF is becoming
widely recognised as a prognostic marker, with the
presence of an activating mutation in stage IV being
associated with very poor prognosis.2 6–8
Mutational activation of PIK3CA9 or loss of pTEN
protein expression10 11 has been implicated in
driving signalling through the AKT pathway, which
is a feature in up to 30% of CRC. While not being
used initially to randomise patients, mismatch
repair (MMR) status is being determined in order
to further stratify patients in the post-
randomisation phase.
The aim of this study was to carry out a pre-trial
analytical validation between the two designated
biomarker testing laboratories in Leeds and Cardiff,
in order to identify the inter-observer laboratory
agreement on 97 samples of stage IV CRC and to
ensure that laboratory testing was accurate and ﬁt
for purpose in both laboratories.
MATERIALS AND METHODS
Samples
Ninety-seven FFPE tumour resection blocks, from
patients previously entered into either the FOCUS3
trial12 or consented outside clinical trial to the
Wales Cancer Bank (WCB), and stored with prior
consent for further use in research, were retrieved
from the WCB. The matched diagnostic biopsy
blocks were also retrieved in 14 cases, to reﬂect the
fact that 20–40% of patients in FOCUS4 will only
have biopsy samples available for analysis. From the
outset, these biopsies were only intended to be
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used for pTEN immunohistochemical analysis. For the purpose
of this validation, the blocks were anonymised before sending
to the biomarker teams in the laboratories in Cardiff and Leeds.
All blocks were initially sent to the Cardiff laboratory for
processing, before being forwarded to Leeds for identical pro-
cessing. Both laboratories were therefore able to carry out all
assay analyses completely independently, representative of the
process of analysis from sample receipt, to the reporting of the
results to the Clinical Trials Unit.
Sample processing
A series of 5 mm thick sections were taken from each block, the
ﬁrst of which was used for H&E staining, to identify the area of
greatest tumour density, and the rest made available for DNA
extraction and whole section (w/s) immunohistochemistry
(IHC). From the residual blocks, tissue microarrays (TMAs)
were then created comprising four 0.6 mm tumour tissue cores
and one core, if available, of ‘tumour-associated’ normal tissue.
In order to reduce tissue use, the TMAs were only prepared
once, in Cardiff, and then shipped to Leeds, where sections
were cut and used for IHC.
DNA macrodissection and extraction
The spare sections from the resection blocks were marked out
for the richest areas of neoplastic cell content, using the corre-
sponding H&E-stained section as a guide, and macrodissected.
DNA was extracted in Leeds using the QIAGEN QIAamp DNA
Extraction Kit (QIAGEN, Skelton House, Manchester, England,
UK), and in Cardiff using the manufacturer’s standard protocol,
on the QIAGEN EZ1 (QIAGEN, Skelton House, Manchester,
England, UK).
Mutation detection
Analysis of mutation hotspots within KRAS codons 12, 13, 61
and 146 (exons 2, 3 and 4), BRAF codon 600 (exon 15), NRAS
codons 12, 13 and 61 (exons 2 and 3) and PIK3CA codons 542,
545, 546 and 1047 (exons 9 and 20) was carried out by pyrose-
quencing. Pyrosequencing was carried out in each lab using a
PyroMark Q96 (QIAGEN, Skelton House, Manchester,
England, UK) (see online supplementary appendix 1). A nega-
tive water control and a positive control for each assay were
included in every sample run. Raw data ﬁles were used to gener-
ate pyrograms for interpretation by qualiﬁed personnel.
MMR status determination
All four immunohistochemical analyses were carried out on a
DAKO Autostainer Link 48 (DAKO, Ely, England, UK) using
DAKO pre-programmed protocols, available with the
Autostainer. Antigen retrieval was performed in the accompany-
ing PT-Link chamber with High pH DAKO Target Retrieval
Solution, according to manufacturer’s instructions (DAKO, Ely,
England, UK). Slides were rinsed with DAKO wash buffer prior
to loading into the Autostainer. DAKO ready-to-use antibodies
were used for MLH1 (IR079), MSH2 (IR085) and MSH6
(IR086). DAKO PMS2 (M3674) was used at a dilution of 1:40.
Sections from the two validation TMAs were stained with each
Ab, then corresponding whole sections were also stained in
cases where the cores appeared negative or equivocal or for
cases where all cores had been lost from the TMA section.
Tumours were deemed positive, if any proportion of the tumour
nuclei was positively stained, or negative, where all discernible
tumour nuclei were negative, in the local presence of positively
staining stromal and inﬁltrating lymphocytic cells (ﬁgure 2). Any
Figure 1 Schematic representation of FOCUS4. *Hierarchical ordering of the molecular cohorts from A through N. CRC, colorectal cancer; EREG,
epiregulin; EGFR, epidermal growth factor receptor; FFPE, formalin-ﬁxed, parafﬁn-embedded; HER, human epidermal growth factor receptor; IHC,
immunohistochemistry; MMR, mismatch repair, OS, overall survival; P, placebo; PFS, progression-free survival; Rx, treatment. http://www.focus4trial.org/.
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samples appearing wholly negative with respect to both tumour
and stromal components were deemed to be of indeterminate
status.
pTEN protein expression
Immunohistochemical staining was carried out using the DAKO
Autostainer Link 48 (DAKO, Ely, England, UK). Antigen
retrieval was carried out in the accompanying PT-Link chamber
with High pH DAKO Target Retrieval Solution, according to
manufacturer’s instructions. Slides were rinsed with DAKO
wash buffer prior to loading into the Autostainer. DAKO pTEN
Ab (M3627) (DAKO, Ely, England, UK) was used at a pre-
determined dilution of 1:100. Both validation TMAs were
stained, along with all corresponding whole sections. The pres-
ence and intensity grade of cytoplasmic staining in the tumour
component was noted (0=negative; 1=weak cytoplasmic stain-
ing, less intense than the surrounding stroma; 2=moderate cyto-
plasmic staining, where staining is equal in intensity to the
adjacent stromal staining and 3=strong cytoplasmic staining,
where staining is stronger in intensity to the adjacent stromal
staining) (ﬁgure 3). For the purposes of randomised stratiﬁcation
of patients, any positive result was reported as ‘no loss’ of
pTEN; whereas the negative result was reported as ‘absence’ of
pTEN. Three FFPE cell lines (LNCaP, pTEN negative; ZR-75-1,
a weak expresser of pTEN and MCF7 which overexpresses
pTEN) were used to create a mini control TMA, which was
Figure 2 Mismatch repair immunohistochemistry (MMR IHC). (A and B) Positive and negative MLH1 tumours are shown, respectively. (C and D)
Positive and negative MSH2 tumours are shown, respectively. (E and F) Positive and negative MSH6 tumours are shown, respectively. (G and H)
Positive and negative PMS2 tumours are shown, respectively (×200 magniﬁcation).
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stained along with each section. A suspension was generated
from each cell line, which was subsequently spun down, ﬁxed in
10% neutral-buffered formalin (NBF), added to 12% Noble
agar at a 1:1 ratio, processed and parafﬁn embedded. Three
cores were taken from each and embedded into a new parafﬁn
block to create the mini ‘control TMA’. A section of this was cut
onto the same slide as each of the 97 validation samples.
Data validation
Each laboratory sent their results of all analyses directly to the
Medical Research Council (MRC) Clinical Trials Unit for inde-
pendent cross-referencing. Any discrepant results were discussed
between the biomarker teams from both laboratories until a
ﬁnal unanimous result was agreed upon.
RESULTS
Mutation detection
The 97 resection samples were subjected to mutation detection
by pyrosequencing at the following mutation hotspots: KRAS
12/13, KRAS 61, KRAS 146, BRAF codon 600, NRAS 12/13,
NRAS 61, PIK3CA exon 9 and PIK3CA exon 20. Mutation rates
at each mutation hotspot were as expected (table 1). Two
samples in Leeds and three samples in Cardiff were deemed to
have ‘failed’ as they only passed ≤3 assays. There were only two
discrepant cases between the two laboratories (table 2). The ﬁrst
of these was deemed PIK3CA wild type (WT) in Cardiff, but
shown to contain an exon 9 mutation (c.1633G>A) in Leeds.
The second sample was PIK3CA WT in Leeds, but found to
contain an exon 20 mutation (c.3140A>G) in Cardiff.
pTEN protein expression
Concordance between laboratories for corresponding whole
sections
Each of the 97 whole sections was stained with pTEN and the
results were compared between the two laboratories. In all
pTEN-positive cases, tumour cells appeared to show cytoplas-
mic distribution of the staining, with a variable proportion
showing in addition, some nuclear staining. There were 88
(90.7%) concordant cases, 6 (6.2%) discordant cases and 3
(3.1%) cases where data were only available from one lab. For
these latter three tumours, the majority of the tissue had
become detached from the slide during the antigen retrieval
stage, leaving insufﬁcient material to score. The six discordant
cases were discussed and reviewed jointly by both laboratories
Figure 3 pTEN protein expression. (A) Negative, (B) grade 1—weak cytoplasmic staining, less intense than the surrounding stroma, (C) grade
2—moderate cytoplasmic staining, where staining is equal in intensity to the adjacent stromal staining and (D) grade 3—strong cytoplasmic
staining, where staining is stronger in intensity to the adjacent stromal staining (×200 magniﬁcation).
Table 1 The percentage of mutations found at each mutation
hotspot shown for the labs in Leeds and Cardiff
Assay Leeds (% mutations) Cardiff (% mutations)
KRAS codons 12/13 32/97 (33) 31*/94 (33)
KRAS codon 61 3/96 (3.1) 3/95 (3.2)
KRAS codon 146 1/95 (1.1) 1/92 (1.1)
BRAF codon 600 12/96 (12.5) 12/94 (12.8)
NRAS codons 12/13 2/95 (2.1) 2/93 (2.1)
NRAS codon 61 2/95 (2.1) 2/95 (2.1)
PIK3CA codons 542–546 10/95 (10.5) 9/94 (9.6)
PIK3CA codon 1047 1/96 (1.0) 2/93 (2.1)
The percentages reflect the number of samples which yielded a result.
*The discrepancy in mutation detection at KRAS codons 12/13 is due to the fact that
one of the samples which failed testing in Cardiff was found to have a mutation
when tested successfully in Leeds.
Table 2 Summary of failed and discrepant cases between
laboratories
Leeds Cardiff
Failed* samples 14001 and V058 24002, L366 and V058
Partial fails† None None
Discrepant samples
(PIK3CA exon 9) R225 (c.1633G>A) R225 (WT)
(PIK3CA exon 20) L722 (WT) L722 (c.3140A>G)
*A failed sample was classed as a sample where ≤3 assays were amplified
successfully.
†A partial fail was classed as a sample where not every assay worked, but ≥4 assays
were successful.
WT, wild type.
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using virtual slide conferencing (http://www.virtualpathology.
leeds.ac.uk) resulting in eventual agreement in all cases (table 3).
Concordance between TMAs and whole section IHC
According to the design of the FOCUS4 trial, it is planned to
carry out an initial screen of the IHC-based biomarkers on
TMAs, to identify those tumours which are positive for pTEN,
and thus require no further investigation. The corresponding
whole sections from tumours which appear negative, or give an
equivocal result on the TMAs, will subsequently be stained for
pTEN. The two validation TMAs were therefore stained with
the pTEN antibody, and the results were compared with those
of the corresponding 97 whole sections. In Leeds, there were 80
concordant cases and two discordant cases. It was not possible
to compare the remaining 15 tumours because 11 of them were
completely missing from the TMA, due to loss from core
drop-off and the cores from the remaining four cases contained
no tumour cells. In Cardiff, there were 83 concordant cases and
six discordant cases. The remaining eight tumours were not
comparable because the cores had fallen from the TMA in seven
of these, and the ﬁnal tumour was not assessable on the whole
section, due to insufﬁcient tumour tissue.
Comparison of whole section and matched diagnostic biopsy
Fourteen resection samples also had the matched biopsy available
for a pTEN protein expression comparison. Only 8/14 (57.1%)
gave concordant results, with both the biopsy and the resection
being positive. In four samples, the biopsy was scored negative,
whereas the resection was positive (ﬁgure 4). One case showed
the reverse of this, while in the ﬁnal case, the resection was posi-
tive, but the biopsy was equivocal, and hence unscorable.
MMR IHC
An initial screen was carried out on the two validation TMAs
for all four MMR antibodies. As with pTEN, it was planned
that any tumours appearing negative or equivocal, or having
insufﬁcient material on the TMA for analysis, would have the
corresponding whole section stained.
The results are given in table 4. In terms of the numbers of
tumours giving a discrepant result (ie, where there was a result
submitted by each lab, and this result differed), there were only
three discrepant cases, although for one tumour (V007) the
result for each of the MMR proteins differed (table 5). Each
case was reviewed jointly, with the two laboratories using virtual
slide conferencing (http://www.virtualpathology.leeds.ac.uk) and
a consensus score was agreed upon for each case.
DISCUSSION
The FOCUS4 clinical trial is designed to provide a further sig-
niﬁcant step forward on the road to more effective biomarker
driven, adaptive trial design in solid tumour oncology, where
the opportunity to add putative predictive biomarkers to the
current panel will be possible. In order for this type of trial to
succeed, there must be complete conﬁdence in the abilities of
the laboratories carrying out the biomarker assay procedures. To
this end, the rigorous pre-trial analytical validation was meticu-
lously planned and carried out over several months in both
laboratories, with 97 anonymised advanced CRC FFPE resec-
tion blocks and 14 matched biopsy blocks. It needed to be
demonstrated that the samples could be processed and concord-
ant results could be obtained in a timely manner. By transferring
the samples between laboratories for processing, this ensured
that each site was independently responsible for the total assay
procedure from preparation of their own sections to the com-
pletion of assay, including interpretation, scoring and reporting
of the results, and in transferring these directly to the MRC for
collation; this kept each laboratory blinded to the results
obtained in the other laboratory.
There was a very high concordance rate between the pyrose-
quencing results. Out of 97 resection samples assayed across all
mutation hotspots, there were only two samples producing a
different outcome, both within PIK3CA. It has to be acknowl-
edged that the sensitivity of pyrosequencing lies somewhere
Table 3 pTEN discrepant cases between the two laboratories
pTEN discrepant case Leeds result Cardiff result Consensus result
3018 Positive Negative Positive
26018 Positive Negative Positive
46031 Positive Negative Positive
48002 Negative Positive Positive
L403 Negative Positive Negative
V007 Positive Negative Positive
Discrepant cases were so labelled, where a result of the whole section staining for a
particular case was generated in both laboratories, but these results differed. There
were only six samples, where this was the case for pTEN.
Figure 4 pTEN protein expression in (A) resection and (B) matched biopsy specimen, highlighting the difference in expression between both
samples. The resection sample was graded as ‘no loss’ of expression, whereas the biopsy sample was graded as ‘loss of expression’ (×200
magniﬁcation).
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between 5% and 25% mutant alleles in a background of WT
alleles, so that in cases where low-level mutations are present,
they may not always be detected. Tumour heterogeneity is a
further complicating factor which could account for the failure
to detect a mutation, particularly where a different part of the
same FFPE block is sampled for testing13 as was the case in this
validation exercise. It is acknowledged that the in-house pyrose-
quencing assays have slight variations in the primer and probe
sequences. The high concordance rates during this validation,
and a previous validation prior to the FOCUS3 trial,12 have
convinced us that these differences are non-consequential.
During the course of the FOCUS4 trial, it is expected that both
laboratories will advance to a Next Generation Sequencing plat-
form, revalidate the changed technique and in doing so, increase
the sensitivity of mutation detection to between 1% and 5%.
The fact that there were only six (6/97, 6.2%) cases discordant
between the two laboratories for pTEN, and only ﬁve (5/388,
1.3%) discrepancies for the MMR antibodies, was reassuring.
Several factors were thought to contribute to the differences
observed. These included the amount of necrosis observed within
the tumour, and also the presence of excessive levels of mucin.
Staining artefacts such as over-counterstaining and ‘edge effect’
were also noted to cause interpretation difﬁculties. One tumour
(V007), which showed discrepant results for each of the ﬁve anti-
bodies, was a signet-ring cell cancer. A large proportion of
signet-ring cells were found to be bloated with mucin and as a
result, had very scant cytoplasm available to show the presence of
pTEN staining in a 5-mm thick section. A consensus opinion was
agreed for each protein, but it was felt that in future, tumours
showing unusual morphology should undergo joint review by
both laboratories prior to reporting the results.
When the 14 matched biopsy samples were stained with the
pTEN antibody, it was surprising to see that six of the tumours
showed discrepancies between the biopsy and resection. In
order to understand this further, an interrogative approach was
adopted towards the samples and their processing, initially
focused on biopsy material. It transpired that in the ﬁve samples
where the biopsy was negative or equivocal and the resection
specimen positive, that the biopsies had been taken and pro-
cessed in one hospital, where at the time, acidiﬁed formalin-ﬁx-
ation was routinely used, while the resection specimen was
taken in another hospital, where neutral buffered formalin was
used. From the extensive data gathered for the COIN Trial,8 the
use of acidiﬁed formalin appeared to have ceased in all labora-
tories in the UK since 2005 because of its deleterious effect on
DNA, with formol saline or neutral buffered formalin being
adopted widely as less deleterious ﬁxatives.
Recent work has focused on the poor reproducibility of
pTEN IHC scoring14 and indeed within the published literature
the quoted rates of pTEN-negative tumours in CRC vary
greatly. Here we have rigorously undertaken analysis of this bio-
marker, including full workup from FFPE blocks in two inde-
pendent laboratories and following independent scoring, have
shown closely adherent results. The addition of cell-line control
TMAs to each slide will continue throughout the FOCUS4 trial.
It has been demonstrated here that two reference laboratories
can independently obtain highly concordant biomarker results
across a wide panel of assays on a large number of samples.
Unfortunately, there was insufﬁcient material remaining at each
laboratory to repeat all assays and ascertain the local reproducibil-
ity rates for all assays. This exercise has highlighted issues which
can potentially make interpretation more difﬁcult, so that should
they arise during the course of the FOCUS4 trial, a web-linked
protocol is now in place to allow joint discussion between labora-
tories. It has also been agreed that a continuous inter-laboratory
validation will take place for the duration of the trial, with each
laboratory supplying three samples on alternate months to the
other laboratory for conﬁrmatory testing. Each laboratory will also
continue to participate in the UK NEQAS molecular genetic
analysis of CRC external quality assurance (EQA) scheme; this cur-
rently (as of 2013) includes analyses for KRAS, NRAS, BRAF and
PIK3CA. With all these measures in place, we are conﬁdent that
molecular testing will continue to be delivered with high and
exacting standards from these designated testing laboratories.
Going forward in personalised medicine trials, we would recom-
mend the use of centralised testing, identical protocols, pre-trial
validation of techniques, continuous quality control and independ-
ent review of the testing by the trials unit.
Take home messages
▸ With many clinical trials reliant upon biomarker analyses for
patient randomisation, it is imperative that conﬁdence in the
laboratories carrying out the analyses is established. The
inter-laboratory validation carried out here is an example of
how this can be established.
▸ Of equal importance is the identiﬁcation of issues which
make the interpretation of biomarker results difﬁcult, and
the putting into place mechanisms to overcome this.
▸ Laboratories must be transparent regarding their assay
validations, in order to inspire the necessary levels of
conﬁdence in their abilities. Publication would seem to be
the obvious route to take to ensure this.
Table 5 Mismatch repair (MMR) discrepant cases between the
two laboratories
MMR
marker
Discrepant case
(s)
Leeds
result
Cardiff
result
Consensus
result
MLH1 V007 Positive Negative Positive
MSH2 V007 Positive Negative Positive
MSH6 V007 Positive Negative Positive
PMS2 V007 Positive Negative Positive
PMS2 V442 Negative Positive Negative
Discrepant cases were so labelled, where a result of the whole section staining for a
particular case was generated in both laboratories, but these results differed. One
sample (V007) was discrepant for all four proteins, and one other case (V442) gave a
discrepant result for PMS2 only.
Table 4 Summary of mismatch repair (MMR)
immunohistochemistry, showing the distribution of positive and
negative cases for each antibody in both labs
Laboratory
MMR
marker
Positive
cases (%)
Negative
cases (%)
No result or
equivocal (%)
Leeds MLH1 90 (92.8) 6 (6.2) 1 (1.0)
Cardiff MLH1 90 (92.8) 6 (6.2) 1 (1.0)
Leeds MSH2 95 (97.9) 1 (1.0) 1 (1.0)
Cardiff MSH2 96 (99.0) 1 (1.0) 0
Leeds MSH6 92 (94.8) 3 (3.1) 2 (2.1)
Cardiff MSH6 94 (96.9) 3 (3.1) 0
Leeds PMS2 88 (90.7) 7 (7.2) 2 (2.1)
Cardiff PMS2 89 (91.8) 7 (7.2) 1 (1.0)
For each protein, the same number of negative cases was identified in both labs.
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